A brief description

At its root, liquid biopsy is an in vitro diagnostic test, a test that takes place outside of a living organism, for example in a test tube or culture dish. In vitro tests are indispensable, informing approximately 70% of clinical decision-making.¹

Liquid biopsies diagnose disease by identifying relevant biomarkers within a liquid substance. The World Health Organisation (WHO) defines biomarkers as “any substance, structure, or process that can be measured in the body or its products and influence or predict the incidence of outcome or disease”. Well-known and widely-measured examples of biomarkers include glucose or cholesterol. Although liquid biopsy is commonly associated with blood samples, some biomarkers can also be detected in urine and saliva.¹

¹CDC. https://www.cdc.gov/csels/dls/strengthening-clinical-labs.html

A disruptive promise

Liquid biopsy aims to displace the current diagnostic paradigm in biopsy: tissue-based biopsy. Liquid biopsy has three critical advantages over its tissue-based counterpart.

1. Liquid biopsies are non-invasive, while tissue biopsies are an invasive, and at times risky procedures, especially when the tumour/disease site is difficult to access. In a tissue biopsy, a piece of tissue is identified through imaging, then surgically removed from the body and lastly, tested for biomarkers. In contrast, liquid biopsies only require a blood draw.

2. Liquid biopsies generate a complete genetic profile of the tumour/disease. This is in stark contrast to tissue biopsies, which are less effective for diseases characterised by regional heterogeneity, such as cancer.

3. Liquid biopsies enable repeat testing at fast turnaround times, which is critical for determining treatment efficacy and tumour/disease evolution. Due to their invasive nature, tissue biopsies are unable to offer either of these benefits.

Authored by:

Maxine Willie, CFA
Investment Analyst, Regnan Equity Impact Solutions team
Liquid biopsy vs. traditional biopsy

<table>
<thead>
<tr>
<th>Liquid biopsy</th>
<th>Traditional biopsy</th>
</tr>
</thead>
<tbody>
<tr>
<td>CTCs</td>
<td>Sample derived from body fluid (usually blood)</td>
</tr>
<tr>
<td>cfDNA</td>
<td>Sample derived from surgical biopsy or needle biopsy</td>
</tr>
<tr>
<td>cfRNA</td>
<td></td>
</tr>
<tr>
<td>Exosomes</td>
<td></td>
</tr>
<tr>
<td>Non-invasive</td>
<td>Invasive</td>
</tr>
<tr>
<td>Less risk and pain</td>
<td>Some risk and pain</td>
</tr>
<tr>
<td>Easily and repeatedly obtained</td>
<td>Often not easily or repeatedly obtained</td>
</tr>
<tr>
<td>Real time detection of comprehensive tissue profile</td>
<td>Spatially and temporally limited tissue profile</td>
</tr>
</tbody>
</table>

Source: researchgate.net
Cancer diagnosis and treatment remains an immense challenge due to the disease’s insidious, shapeshifting quality. Liquid biopsy could prove a revolutionary diagnostic weapon against cancer due to its potential to monitor disease progression in real-time, allowing clinicians to rapidly adapt the treatment response to the quickly-evolving cancer. Cancer “invades” the body through the bloodstream, via a process called metastasis. As they metastasize, most solid cancers shed either entire cells, or fragments of cells into said bloodstream. Both cells and cellular fragments are biomarkers which liquid biopsies aim to detect.

According to the WHO, cancer is responsible for 1 in 6 deaths worldwide, 70% of which occur in low- to middle-income countries.

A promising solution for cancer diagnosis

Although it can be used for other applications, the excitement around liquid biopsy springs from its potential to diagnose cancer. Cancer remains one of the world’s deadliest and fastest growing diseases. According to the WHO, cancer is responsible for 1 in 6 deaths worldwide, 70% of which occur in low- to middle-income countries.

Cancer diagnosis and treatment remains a gargantuan challenge due to the disease’s insidious, shapeshifting quality:

“Cancer is an expansionist disease; it invades through tissues, sets up colonies in hostile landscapes, seeking “sanctuary” in one organ and then immigrating to another. It lives desperately, inventively, fiercely, territorially, cannily, and defensively—at times, as if teaching us how to survive. To confront cancer is to encounter a parallel species, one perhaps more adapted to survival than even we are.”

Source: Siddhartha Mukherjee, The Emperor of All Maladies

Predicted global cancer cases, 2012–2035

Cases (millions)

<table>
<thead>
<tr>
<th>Year</th>
<th>World</th>
<th>Less developed countries</th>
<th>More developed countries</th>
</tr>
</thead>
<tbody>
<tr>
<td>1990</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2025E</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2030E</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2035E</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: WHO GloboCan, BBC.
A multi-market opportunity

Although the origins of liquid biopsy date back to the 19th century, it was the rapid evolution and plummeting costs of its two base technologies, next-generation sequencing (NGS) and polymerase chain reaction (PCR), that propelled it into commerciality in the 21st century. However, the liquid biopsy market remains nascent and future market size estimates diverge significantly, spanning from approximately $20 to $100 billion. Notably, the size of the entire in vitro diagnostics market is estimated to be approximately $60 billion.

To put it simply, the size of the total addressable market depends on how early liquid biopsy can diagnose cancer. Earlier-stage cancers are easier to treat as they are more localised and are less likely to have metastasized significantly beyond their place of origin. The importance of earlier detection applies to almost all cancers: the average 5-year survival rate of early-stage cancer is 91%, which drops to 26% for later stage cancers. However, the significance of early detection can vary significantly between cancers: The five-year survival rate for prostate cancer for instance is 99%, in stark contrast to the five-year survival rate for pancreas cancer, which is 8%.

The problem is that early cancer detection is technically more difficult. Earlier-stage, localised cancers shed less genetic material into the bloodstream. This low volume of cancerous cells or cellular fragments results in a high signal-to-noise ratio, making detection more difficult.

The most established but smallest market for liquid biopsy is therapy selection for late-stage cancers. Here, the clinical evidence base is most robust, and liquid biopsy is used for both companion diagnostics, a test associated with a targeted therapy, and clinical diagnostics. Today, liquid biopsy is thus mainly used to predict treatment response. A less established but bigger market is the monitoring market. Here, liquid biopsy can be used on a long-term basis to monitor treatment response and disease recurrence.

However, the real excitement is sparked by liquid biopsy’s potential for early detection and screening of cancers. The majority of cancers today have no associated screening tests, and a number of companies are developing ‘pan-cancer’ screening tests which aim to detect over 50 types of cancer in a single blood sample.
**Remaining challenges**

**Clinically useful outcomes**
Earlier diagnosis is only useful if the diagnosed cancers can also be treated earlier. In other words, liquid biopsy only lives up to its promises if it improves survival rates of cancer patients. However, increased screening in and of itself creates the illusion of improving 5-year survival rates, even if it doesn’t enable more effective treatment. This is due to the lead time bias, in which a disease is detected earlier, but earlier detection does not change the standard treatment paradigm or course of the disease. Statistics will therefore need to be interpreted with great care.

Even more importantly, current treatment paradigms will need to evolve in order to make early detection of cancer clinically useful. A key hurdle to treatment of early-stage tumours is the identification of their location of origin, which remains a challenge within liquid biopsy. A thyroid cancer screening programme, rolled out in South Korea in 1999 for an asymptomatic population, provides a good example. While it resulted in a higher incidence rate, it did not have an impact on mortality rates⁴.

**Sensitivity and specificity**
Sensitivity and specificity remain a challenge for this fledgling diagnostic tool. As illustrated previously, early-stage tumours only shed low concentrations of cancerous cells or fragments. Low sensitivity in detection results in false negatives, by not being able to detect these low concentrations and means incidents of a disease may go undetected. Low specificity in detection, on the other hand, leads to false positives, whereby the detected biomarkers do not lead to the patient developing the disease at a later stage. Liquid biopsy companies aim to overcome these challenges by combining several tumour-specific biomarkers into a single test. Although the critical threshold levels for each are hotly debated, and vary between different tumours, both remain a challenge for the field.

**Reimbursement**
The pathway to financial reimbursement for diagnostic tests is complex and lengthy, particularly in the US. While liquid biopsies for later-stage cancers benefit from a better-established path, the reimbursement landscape for pan-cancer screening test is much more uncertain. The viability of pan-cancer screening, in terms of coverage from large payors, is likely to hinge on both legislative change and the industry’s ability to drive cost reductions, as molecular diagnostic tests account for a fast-growing share of their expenditure. The onus to demonstrate clinically useful outcomes will therefore be critical to justify the potentially significant expense borne by insurers.

**Lead-time bias**

<table>
<thead>
<tr>
<th>Without screening</th>
<th>With screening</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cancer starts</strong></td>
<td><strong>Cancer starts</strong></td>
</tr>
<tr>
<td>Dead at age 70 years</td>
<td>Dead at age 70 years</td>
</tr>
<tr>
<td>5-year survival = 0%</td>
<td>5-year survival = 100%</td>
</tr>
</tbody>
</table>

*Cancer diagnosed because of symptoms at age 67 y* | *Cancer diagnosed because of symptoms at age 60 y*


⁴Ahn, H. S., Kim, H. J., Kim, K. H., Lee, Y. S., Han, S. J., Kim, Y., … & Brito, J. P. (2016). Thyroid cancer screening in South Korea increases detection of papillary cancers with no impact on other subtypes or thyroid cancer mortality. Thyroid, 26(11), 1535-1540.
Summary

Liquid biopsy’s promise is clear: a noninvasive means to identify and track the evolution of a disease, which in turn allows for continuous tweaking of the treatment regimen. This promise is particularly salient for cancer, a disease characterised by its shapeshifting quality, late-stage detection and more generally, limited diagnostic tests. Nevertheless, liquid biopsy has significant technical and reimbursement hurdles to overcome before it can realise its promise.

References

Ahn, H. S., Kim, H. J., Kim, K. H., Lee, Y. S., Han, S. J., Kim, Y., ... & Brito, J. P. (2016). Thyroid cancer screening in South Korea increases detection of papillary cancers with no impact on other subtypes or thyroid cancer mortality. *Thyroid, 26*(11), 1535-1540.


Regnan is a responsible investment leader with a long and proud history of providing insight and advice to investors and industry bodies such as the UNPRI. In 2020 Regnan expanded into responsible investment funds management, backed by the considerable resources of Pendal Group.

Our strategies:

**Regnan Global Equity Impact Solutions**

The Regnan Global Equity Impact Solutions strategy is a solutions-first approach, focused on investing in mission-driven businesses that address underserved environmental and social challenges and deliver real, systematic change for the better. It is a high-conviction, global, multi-capitalisation portfolio with low turnover and a strong emphasis on driving impact by engaging companies to improve measurable outcomes.

**Regnan Sustainable Water and Waste**

Our Thematic Investing team joined Regnan in April 2021 and launched the Regnan Sustainable Water and Waste Strategy in September 2021. Combining exposure to both water and waste-related companies makes this strategy a distinctive thematic investment proposition with diversification benefits.

**Regnan Credit Impact***

The Regnan Credit Impact Strategy is an actively managed portfolio of mainly investment grade impact bonds (green/climate, social & sustainability) that support positive societal and/or environmental outcomes including advancement of the United Nations Sustainable Development Goals.

*Available to Australian investors only.
Disclaimer

Issued and approved in the UK by J O Hambro Capital Management Limited ("JOHCML") which is authorised and regulated by the Financial Conduct Authority. Registered office: Level 3, 1 St James’s Market, London SW1Y 4AH. Issued in the European Union by JOHCM Funds (Ireland) Limited ("JOHCMI") which is authorised by the Central Bank of Ireland. Registered office: Riverside One, Sir John Rogerson’s Quay, Dublin 2, Ireland.

References to “JOHCM” below are to either JOHCML or JOHCMI as the context requires.

This is a marketing communication. Please refer to the fund prospectus and to the KIID before making any final investment decisions.

These documents are available in English at www.johcm.com, and available from JOHCMI, or (for UK investors) JOHCML, at the addresses set out above.

Information on the rights of investors can be found [here](#).

The distribution of this document in jurisdictions other than those referred to above may be restricted by law ("Restricted Jurisdictions"). Therefore, this document is not intended for distribution in any Restricted Jurisdiction and should not be passed on or copied to any person in such a jurisdiction.

The registrations of the funds described in this document may be terminated by JOHCM at its discretion from time to time.

Notice to Swiss investors: RBC Investor Services Bank S.A., with registered office at Esch-sur-Alzette, Badenerstrasse 567, P.O. Box 1292. CH-8048 Zurich has been appointed to act both in a capacity as Swiss representative and Swiss paying of the JOHCM Global Emerging Markets Opportunities Fund. All legal documentation pertaining to the JOHCM Global Emerging Markets Opportunities Fund can be obtained free of charge from the Swiss representative. The place of performance and jurisdiction in relation to [shares/units] distributed in Switzerland is at the registered office of the Swiss representative.

The investment promoted concerns the acquisition of shares in a fund and not the underlying assets.

Investors should note that this strategy invests in emerging markets and such investments may carry risks with failed or delayed settlement and with registration and custody of securities. Companies in emerging markets may not be subject to accounting, auditing and financial reporting standards or be subject to the same level of government supervision and regulation as in more developed markets. Government involvement in the economy may affect the value of investments in certain emerging markets and the risk of political instability may be high. The reliability of trading and settlement systems in some emerging markets may not be equal to that available in more developed markets which may result in problems in realising investments. Lack of liquidity and efficiency in certain of the stock markets or foreign exchange markets in certain emerging markets may mean that from time to time the fund manager may experience difficulty in purchasing or selling holdings of securities. Furthermore, due to local postal and banking systems, no guarantee can be given that all entitlements attaching to quoted and over-the counter traded securities acquired by this strategy, including those related to dividends, can be realised.

The Fund’s investment includes shares in small-cap companies and these tend to be traded less frequently and in lower volumes than larger companies making them potentially less liquid and more volatile.

The MSCI information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an “as is” basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the “MSCI Parties”) expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages. ([www.msci.com](http://www.msci.com))

The information in this document does not constitute, or form part of, any offer to sell or issue, or any solicitation of an offer to purchase or subscribe for any funds described in this document; nor shall this document, or any part of it, or the fact of its distribution form the basis of, or be relied on, in connection with any contract.
Disclaimer (cont’d)

Telephone calls to and from JOHCM may be recorded. Information on how personal data is handled can be found in the JOHCM Privacy Statement on its website: www.johcm.com

The registered mark J O Hambro® is owned by Barnham Broom Holdings Limited and is used under licence. JOHCM® is a registered trademark of JOHCM.

Regnan is the specialist sustainable and impact investing brand of the Australian-listed asset manager Pendal Group, which encompasses J O Hambro Capital Management, Thompson, Siegel & Walmsley and Pendal Australia. Regnan’s focus is on delivering innovative solutions for sustainable and impact investment, leaning on over 20 years of experience at the frontier of responsible investment. “Regnan” is a registered trademark of Pendal.

The Regnan business consists of two distinct business lines. The investment management business is based in the United Kingdom and sits within J O Hambro Capital Management Limited, which is authorised and regulated by the Financial Conduct Authority and is registered as an investment adviser with the SEC. “Regnan” is a registered as a trading name of J O Hambro Capital Management Limited. The investment team manages the Regnan Global Equity Impact Solutions (RGEIS) strategy which aims to generate market-beating long-term returns by investing in solutions to the world’s environmental and societal problems. The RGEIS strategy is distributed in Australia by Pendal Fund Services Limited.

Alongside the investment team is the Regnan Insight and Advisory Centre of Pendal Institutional Limited in Australia, which has a long history of providing engagement and advisory services on environmental, social and governance issues. While the investment management team will often draw on services from and collaborate with the Regnan Insight and Advisory Centre, they remain independent of the Regnan Insight and Advisory Centre and are solely responsible for the investment management of the RGEIS strategy.

Sources for all data: JOHCM/Bloomberg/Lipper/MSCI Group (unless otherwise stated).